Medical / Clinical Discussions, page-365

This paper looked at FTO overexpression in head and neck cancer (OSCC) and found it was involved in some patients cancers and that inhibiting FTO was a target [1]. There are other papers identifying FTO in other SCC’s [2, 3].

1. Pilžys, T., Marcinkowski, M., Kukwa, W., Garbicz, D., Dylewska, M., Ferenc, K., et al. (2019). ALKBH overexpression in head and neck cancer: potential target for novel anticancer therapy. Nature Publishing Group, 9(1), 13249. http://doi.org/10.1038/s41598-019-49550-x

2. Zhou, S., Bai, Z.-L., Xia, D., Zhao, Z.-J., Zhao, R., Wang, Y.-Y., & Zhe, H. (2018). FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Molecular Carcinogenesis, 57(5), 590–597. http://doi.org/10.1002/mc.22782

3. Liu, J., Ren, D., Du, Z., Wang, H., Zhang, H., & Jin, Y. (2018). m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochemical and Biophysical Research Communications, 502(4), 456–464. http://doi.org/10.1016/j.bbrc.2018.05.175